James E. Fickenscher
2015 - Antares Pharma
In 2015, James E. Fickenscher earned a total compensation of $1.1M as Chief Financial Officer at Antares Pharma, a 402% increase compared to previous year.
Compensation breakdown
Bonus | $1,000 |
---|---|
Non-Equity Incentive Plan | $144,480 |
Option Awards | $227,522 |
Salary | $350,000 |
Stock Awards | $406,192 |
Other | $12,959 |
Total | $1,142,153 |
Fickenscher received $406.2K in stock awards, accounting for 36% of the total pay in 2015.
Fickenscher also received $1K in bonus, $144.5K in non-equity incentive plan, $227.5K in option awards, $350K in salary and $13K in other compensation.
Rankings
In 2015, James E. Fickenscher's compensation ranked 7,302nd out of 13,638 executives tracked by ExecPay. In other words, Fickenscher earned more than 46.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,302 | 47th |
Manufacturing | 2,747 | 47th |
Measuring, Analyzing, And Controlling Instruments; Photographic, Medical And Optical Goods; Watches And Clocks | 355 | 53rd |
Surgical, Medical, And Dental Instruments And Supplies | 197 | 58th |
Surgical and Medical Instruments and Apparatus | 107 | 64th |
Fickenscher's colleagues
We found four more compensation records of executives who worked with James E. Fickenscher at Antares Pharma in 2015.
News
Zynerba Pharmaceuticals CEO Armando Anido's 2022 pay slips 15% to $1.9M
April 21, 2023
Zynerba Pharmaceuticals CEO Armando Anido's 2021 pay jumps 49% to $2.2M
April 25, 2022
Zynerba Pharmaceuticals CEO Armando Anido's 2020 pay rises 8% to $1.5M
April 21, 2021
Zynerba Pharmaceuticals CEO Armando Anido's 2019 pay falls 32% to $1.4M
April 23, 2020
Zynerba Pharmaceuticals CEO Armando Anido's 2018 pay slips 18% to $2M
April 25, 2019